DDrare: Database of Drug Development for Rare Diseases

76. 下垂体性ゴナドトロピン分泌亢進症
［臨床試験数：25，薬物数：41（DrugBank：11），標的遺伝子数：3，標的パスウェイ数：10］

Searched query = "Pituitary gonadotropin secretion hyperthyroidism", "Gonadotropin secreting pituitary adenoma", "Central precocious puberty", "Gonadotropin producing pituitary adenoma"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = Acetate; CPP; Dabu ying pills; Dihuang; Enantone; GnRH; GnRH agonist; Gold; Gonadorelin; Gonadorelin acetate and Triptorelin acetate; Histrelin; Histrelin Subcutaneous Implant; LA; LEUPRORELIN ACETATE; Leuplin; Leuplin DPS 11.25mg; Leuprolide; Leuprolide (GnRH agonists); Leuprolide Acetate (LA); Leuprolide Acetate 3 Month Depot; Leuprolide Acetate 45 mg; Leuprolide acetate 11.25 mg; Leuprolide acetate 30 mg; Leuprolide acetate depot; Leuprorelin; Leuprorelin Acetate 3.75mg Injection; Luphere depot 3.75mg(Leuprolide acetate 3.75mg); Lupron (leuprolide acetate); Megestrol Acetate Tablet; Megestrol acetate; RhGH; TRIPTORELIN; Trade name depends on the source of the product; Trade name depends on the source of the product’; Triptorelin; Triptorelin (GnRH agonists); Triptorelin acetate and Gonadorelin acetate; Triptorelin embonate, Triptorelin pamoate; Triptorlin or Leuprorelin; Zhibo dihuang pills; Ziyinxiehuo Granules Herbs

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02811471 (ClinicalTrials.gov)	June 2016	21/6/2016	Pharmacokinetic Study of Leuprolide Acetate Injectable Suspension in the Treatment of Central Precocious Puberty	An Open-label, Single Arm, Multicenter Study on the Efficacy, Safety, and Pharmacokinetics of Leuprolide Acetate 45 mg for Injectable Suspension Controlled Release in Subjects With Central (Gonadotropin-Dependent) Precocious Puberty—Part A and B	Central Precocious Puberty	Drug: Leuprolide	Nemours Children's Clinic	Tolmar Inc.	Recruiting	2 Years	9 Years	Both	5	Phase 3	United States
2	NCT02452931 (ClinicalTrials.gov)	August 31, 2015	5/5/2015	Study of Leuprolide Acetate Injectable Suspension in the Treatment of Central Precocious Puberty	An Open-label, Single Arm, Multicenter Study on the Efficacy, Safety, and Pharmacokinetics of Leuprolide Acetate 45 mg for Injectable Suspension Controlled Release in Subjects With Central (Gonadotropin-Dependent) Precocious Puberty	Precocious Puberty, Central	Drug: Leuprolide Acetate 45 mg	Tolmar Inc.	NULL	Completed	2 Years	9 Years	All	64	Phase 3	United States;Argentina;Canada;Chile;Mexico;New Zealand

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT02811471
(ClinicalTrials.gov)

June 2016

21/6/2016

Pharmacokinetic Study of Leuprolide Acetate Injectable Suspension in the Treatment of Central Precocious Puberty

An Open-label, Single Arm, Multicenter Study on the Efficacy, Safety, and Pharmacokinetics of Leuprolide Acetate 45 mg for Injectable Suspension Controlled Release in Subjects With Central (Gonadotropin-Dependent) Precocious Puberty—Part A and B

Central Precocious Puberty

Drug: Leuprolide

Nemours Children's Clinic

Tolmar Inc.

Recruiting

2 Years

9 Years

Both

Phase 3

United States

NCT02452931
(ClinicalTrials.gov)

August 31, 2015

5/5/2015

Study of Leuprolide Acetate Injectable Suspension in the Treatment of Central Precocious Puberty

Precocious Puberty, Central

Drug: Leuprolide Acetate 45 mg

Tolmar Inc.

NULL

Completed

2 Years

9 Years

All

Phase 3

United States;Argentina;Canada;Chile;Mexico;New Zealand